PAUL ANDREA (General Counsel) sold 2.2% of their position (3.31K shares) of ZENTALIS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $38.2K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/5/2024ACC: 0001725160-24-000032
Officer· General Counsel
Since Aug 2022
+311.69K
Net shares
Net buyer
$38.2K
Total sold
1
Open market trades
0B · 1S
4
Total transactions
315K acquired · 3.31K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+112.50K
Price / share
—
Trade value
—
% of position
275.9%
2/1/2024
40.78K→153.28K
Common Stock
Direct
Shares
−3.31K
Price / share
$11.54
Trade value
$38.20K
% of position
2.2%
2/2/2024
153.28K→149.97K
Total
Net shares
+109.19K
Net value
-$38.20K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/1/2024 | A · Award | +112.50K | — | — | 275.9% | 40.78K | 153.28K |
| Common Stock Direct | 2/2/2024 | S · Sale | −3.31K | $11.54 | $38.20K | 2.2% | 153.28K | 149.97K |
| Total | +109.19K | -$38.20K | ||||||
Derivative Transactions2
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
112.50K shares
Shares
+112.50K
Strike price
11.69
Held after
112.50K
Exercisable
—
2/1/2024
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
90K shares
Shares
+90K
Strike price
11.69
Held after
90K
Exercisable
—
2/1/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock112.50K shares | 2/1/2024 | A · Award | +112.50K | 11.69 | — | 112.50K |
| Stock Option (Right to Buy) Direct | Common Stock90K shares | 2/1/2024 | A · Award | +90K | 11.69 | — | 90K |